AIM: We aimed to appraise the quality of Chinese Society of Infectious Diseases of China Medical Association clinical practice guidelines (CPGs) for infectious diseases in China. METHODS: We performed the electronic search and hand search on the above-mentioned CPGs for infectious diseases published from January 1997 to October 2017. Each publication was evaluated using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. RESULTS: Thirteen guidelines were identified and enrolled for the further evaluation. The median scores of the AGREE II domains across all 13 guidelines were as follows: scope and purpose 73.61% (36.11% to 84.72%), stakeholder involvement 12.50% (8.33% to 20.83%), rigor of development 19.27% (12.50% to 26.04%), clarity of presentation 86.11% (23.61% to 94.44%), applicability 33.33% (26.04% to 50.00%), and editorial independence 8.33% (4.17% to 16.67%). The clarity of presentation domain got the highest score among the six domains. Moreover, when compared the CPGs by the year of publication (2002 to 2006 vs. 2007 to 2017), the quality scores were higher in the CPGs published in the last 10 years than those published before, but with no significant difference. CONCLUSIONS: The quality score of CPGs for infectious diseases in China from January 1997 to October 2017 was moderate, but had significant shortcomings, especially in the stakeholder involvement and editorial independence domains. However, the AGREE II instrument is useful and feasible for appraising the CPGs and should be applied to develop, implement, and promote the CPGs in China.
AIM: We aimed to appraise the quality of Chinese Society of Infectious Diseases of China Medical Association clinical practice guidelines (CPGs) for infectious diseases in China. METHODS: We performed the electronic search and hand search on the above-mentioned CPGs for infectious diseases published from January 1997 to October 2017. Each publication was evaluated using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. RESULTS: Thirteen guidelines were identified and enrolled for the further evaluation. The median scores of the AGREE II domains across all 13 guidelines were as follows: scope and purpose 73.61% (36.11% to 84.72%), stakeholder involvement 12.50% (8.33% to 20.83%), rigor of development 19.27% (12.50% to 26.04%), clarity of presentation 86.11% (23.61% to 94.44%), applicability 33.33% (26.04% to 50.00%), and editorial independence 8.33% (4.17% to 16.67%). The clarity of presentation domain got the highest score among the six domains. Moreover, when compared the CPGs by the year of publication (2002 to 2006 vs. 2007 to 2017), the quality scores were higher in the CPGs published in the last 10 years than those published before, but with no significant difference. CONCLUSIONS: The quality score of CPGs for infectious diseases in China from January 1997 to October 2017 was moderate, but had significant shortcomings, especially in the stakeholder involvement and editorial independence domains. However, the AGREE II instrument is useful and feasible for appraising the CPGs and should be applied to develop, implement, and promote the CPGs in China.